Buddleja Saligna Extracts for Melanoma Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for melanoma lack FDA-approved anti-angiogenic drugs, and existing compounds targeting regulatory factors for melanoma, such as VEGF, IL-8, IL-6, COX-2, and sphK1, have limited efficacy and potential side effects.
Innovation Solution
The use of extracts from Buddleja saligna, specifically containing oleanolic acid and ursolic acid, to inhibit angiogenesis and proliferation of melanoma cells by targeting these regulatory factors, while also providing sunscreen protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds targeting regulatory factors (VEGF, IL-8, IL-6, COX-2, sphK1) are used to treat melanoma, then some anticancer effect is achieved, but efficacy is limited and side effects occur
Solution Approach 1:
The patent extracts and isolates specific bioactive compounds (oleanolic acid and ursolic acid) from the Buddleja saligna plant. This extraction process concentrates the therapeutic components responsible for inhibiting angiogenesis and melanoma cell proliferation, thereby improving anticancer efficacy while potentially reducing unnecessary side effects associated with broader-spectrum compounds
Solution Approach 2:
The patent utilizes a composite approach by combining multiple bioactive compounds (oleanolic acid and ursolic acid) from the same plant source. This composite mixture synergistically targets multiple regulatory factors simultaneously, enhancing overall anticancer efficacy while maintaining a favorable safety profile
2Reliability
If regulatory factors are inhibited to stop angiogenesis, then melanoma growth is suppressed, but normal angiogenic processes (wound healing, reproductive cycle) may be affected
Solution Approach 1:
The bioactive compounds from Buddleja saligna exhibit selective action, preferentially targeting pathological angiogenesis in melanoma tumors while sparing normal physiological angiogenic processes. This local quality of action allows effective anti-angiogenic therapy without significantly impacting wound healing, reproductive functions, or other normal vascular development processes
3Productivity
If UV radiation exposure occurs, then melanocytes are stimulated, but uncontrolled growth and skin damage result
Solution Approach 1:
The patent applies the Buddleja saligna extract or isolated compounds as a preventive measure before UV-induced damage occurs. The bioactive compounds pre-condition the skin by inhibiting the pathological signaling pathways that would otherwise lead to uncontrolled melanocyte proliferation and skin damage upon UV exposure, thereby preventing melanoma development while allowing normal melanin production
Data Source
AI summary
The invention relates to an extract from Buddleja saligna, or a bioactive mixture consisting essentially of oleanolic acid and ursolic acid isolated from Buddleja saligna, for use in preventing and/or treating skin cancer, more specifically melanoma, and for reducing skin damage resulting from UV radiation. The invention also relates to uses and methods of treating skin cancer and reducing skin damage resulting from UV radiation using the extracts and/or bioactive mixture described. The invention further relates to an anticancer composition comprising the extracts and/or bioactive mixture, that inhibits angiogenesis and/or proliferation of cells associated with melanoma, as well as a sunscreen composition comprising the extracts and/or bioactive mixture.